- Home
- RDI vs ITRM Comparison
RDI vs ITRM Comparison
Compare RDI & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- ITRM
- Stock Information
- Founded
- RDI 1937
- ITRM 2015
- Country
- RDI United States
- ITRM Ireland
- Employees
- RDI N/A
- ITRM N/A
- Industry
- RDI Movies/Entertainment
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- ITRM Health Care
- Exchange
- RDI Nasdaq
- ITRM Nasdaq
- Market Cap
- RDI 35.7M
- ITRM 40.0M
- IPO Year
- RDI N/A
- ITRM 2018
- Fundamental
- Price
- RDI $1.49
- ITRM $0.68
- Analyst Decision
- RDI
- ITRM Strong Buy
- Analyst Count
- RDI 0
- ITRM 2
- Target Price
- RDI N/A
- ITRM $7.00
- AVG Volume (30 Days)
- RDI 75.7K
- ITRM 825.4K
- Earning Date
- RDI 08-14-2025
- ITRM 08-05-2025
- Dividend Yield
- RDI N/A
- ITRM N/A
- EPS Growth
- RDI N/A
- ITRM N/A
- EPS
- RDI N/A
- ITRM N/A
- Revenue
- RDI $219,213,000.00
- ITRM N/A
- Revenue This Year
- RDI $5.21
- ITRM N/A
- Revenue Next Year
- RDI $11.45
- ITRM $249.35
- P/E Ratio
- RDI N/A
- ITRM N/A
- Revenue Growth
- RDI 7.59
- ITRM N/A
- 52 Week Low
- RDI $1.17
- ITRM $0.61
- 52 Week High
- RDI $1.89
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- RDI 54.81
- ITRM 40.48
- Support Level
- RDI $1.49
- ITRM $0.61
- Resistance Level
- RDI $1.57
- ITRM $0.75
- Average True Range (ATR)
- RDI 0.07
- ITRM 0.06
- MACD
- RDI 0.00
- ITRM -0.01
- Stochastic Oscillator
- RDI 51.52
- ITRM 22.70
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.